Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Taylor

Showing results (101-110 of 138) with videos related to

Pageof 14
Sort By:
Blood|July 30, 2025
XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid MalignanciesTraci L Kruer, Ariel Quintana-Gonzalez, Hannah L Newman, et al.
American Journal of Hematology|March 2, 2021
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapyBrian J Ball, Meier Hsu, Sean M Devlin, et al.
Blood Neoplasia|June 2, 2025
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemiaEllen Madarang, Jillian Lykon, Wei Zhao, et al.
Blood|August 13, 2017
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterationsBenjamin H Durham, Bartlomiej Getta, Sascha Dietrich, et al.
Blood|June 4, 2017
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMMLAkihide Yoshimi, Maria E Balasis, Alexis Vedder, et al.
Cancer Research|June 18, 2025
XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome ChemoresistanceTulasigeri M Totiger, Wannasiri Chiraphapphaiboon, Yasmine Baca, et al.
Haematologica|February 26, 2026
Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.
Cancer Cell|August 15, 2018
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene MutationsStanley Chun-Wei Lee, Khrystyna North, Eunhee Kim, et al.
The Journal of Clinical Investigation|June 20, 2018
Oncogenic TRK fusions are amenable to inhibition in hematologic malignanciesJustin Taylor, Dean Pavlick, Akihide Yoshimi, et al.
Cancer Discovery|July 29, 2022
Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic TransformationSisi Chen, Rahul S Vedula, Antonio Cuevas-Navarro, et al.
Pageof 14

Showing results (101-110 of 138) with videos related to

Sort By:
Pageof 14
Blood|July 30, 2025
XPO1 Drives Resistance to Eprenetapopt and Azacitidine and Can Be Targeted in TP53-Mutated Myeloid MalignanciesTraci L Kruer, Ariel Quintana-Gonzalez, Hannah L Newman, et al.
American Journal of Hematology|March 2, 2021
The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapyBrian J Ball, Meier Hsu, Sean M Devlin, et al.
Blood Neoplasia|June 2, 2025
Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemiaEllen Madarang, Jillian Lykon, Wei Zhao, et al.
Blood|August 13, 2017
Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterationsBenjamin H Durham, Bartlomiej Getta, Sascha Dietrich, et al.
Blood|June 4, 2017
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMMLAkihide Yoshimi, Maria E Balasis, Alexis Vedder, et al.
Cancer Research|June 18, 2025
XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome ChemoresistanceTulasigeri M Totiger, Wannasiri Chiraphapphaiboon, Yasmine Baca, et al.
Haematologica|February 26, 2026
Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.
Cancer Cell|August 15, 2018
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene MutationsStanley Chun-Wei Lee, Khrystyna North, Eunhee Kim, et al.
The Journal of Clinical Investigation|June 20, 2018
Oncogenic TRK fusions are amenable to inhibition in hematologic malignanciesJustin Taylor, Dean Pavlick, Akihide Yoshimi, et al.
Cancer Discovery|July 29, 2022
Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic TransformationSisi Chen, Rahul S Vedula, Antonio Cuevas-Navarro, et al.
Pageof 14